Most people have heard of fentanyl, the synthetic opioid driving today’s overdose deaths. But the fentanyl in today’s drug supply is not always fentanyl. Often it is a chemical cousin: an analog built to act like fentanyl but with a slightly different structure, different enough to slip past drug tests and stay one step ahead of the law. Some of these analogs are far more potent than fentanyl itself.
Knowing what fentanyl analogs are, and why they are so hard to identify, matters for anyone touched by the fentanyl crisis. For people using drugs, it can mean not knowing what they are actually taking. For families, it can help explain how someone could overdose on something a toxicology screen didn’t even catch.
What Is a Fentanyl Analog?
A fentanyl analog is a compound that shares the core chemical structure of fentanyl but has been changed in some way. These changes can dramatically affect how potent the drug is and how easily it can be detected, but the analog still acts on the same opioid receptors and can still cause the slowed or stopped breathing that makes an overdose deadly.
The range of potency across fentanyl analogs is enormous. Some are weaker than fentanyl, while others are vastly stronger. Carfentanil, one of the most potent, is estimated to be about 10,000 times stronger than morphine and 100 times stronger than fentanyl. Analogs can also be so similar to one another that standard drug tests cannot tell them apart, even when the danger they pose is very different.
Why Analogs Are Deliberately Created
Fentanyl analogs in the illicit supply are not accidents of chemistry. They are deliberately engineered, primarily for three purposes. As the Pacific Northwest National Laboratory’s analysis of fentanyl analogs documents, chemists create new analogs to avoid classification as illegal substances, to evade detection in standard drug tests, and to get around manufacturing restrictions. Before the DEA placed fentanyl-related substances under class-wide scheduling in 2018, traffickers could manufacture and distribute a new analog until the DEA scheduled it individually, a slow process that traffickers exploited by simply releasing the next new compound.
These analogs are not the work of isolated operators. According to the DEA’s National Drug Threat Assessment, the Sinaloa Cartel and the Jalisco New Generation Cartel (CJNG) are the primary organizations producing illicit fentanyl and trafficking it into the United States. They manufacture the drug in clandestine laboratories in Mexico using precursor chemicals and pill presses sourced largely from companies in China, and they control the distribution networks that move it across the border. In early 2025, both cartels were designated as foreign terrorist organizations by the U.S. government.
The financial incentive is enormous, and so is the danger. By the DEA’s estimate, a single kilogram of fentanyl carries enough lethal doses to kill about 500,000 people. The analog market runs on the same economics: a new, unscheduled compound can be made and sold with less legal risk while producing a similar effect for the user, and the same lethal unpredictability.
That unpredictability is not incidental. When cartels adulterate the supply with novel analogs and other synthetic additives, they are effectively running an uncontrolled experiment on the people who buy it. No one tests these compounds for safety, no one measures the dose, and the person using the drug has no way to know what they have taken or how strong it is. Each new analog introduced into the supply is, in practice, tried out on the public for the first time at the point of sale.
The Main Analogs: Carfentanil, Acetylfentanyl, and Fluorofentanyl
Three analogs have been among the most consistently documented in the illicit supply and in overdose deaths.
Carfentanil
Carfentanil is the most potent fentanyl analog encountered in the illicit supply, estimated to be about 100 times more potent than fentanyl and 10,000 times more potent than morphine. Its only approved use is as a tranquilizer for large animals in veterinary medicine; it has no approved human use. Its potency has made it a documented mass-casualty agent: a 2012 forensic analysis of casualties from the 2002 Moscow theater siege confirmed that the aerosol Russian forces used contained carfentanil, in an event that caused about 125 deaths. In the U.S. illicit supply, carfentanil has appeared in street fentanyl and been linked to clusters of overdose deaths, and after years of only sporadic detection it has reemerged more recently as a cause of fatal overdoses.
Acetylfentanyl
Acetylfentanyl is roughly one-third as potent as fentanyl (and about 16 times as potent as morphine), but it has appeared frequently in overdose deaths, in part because it can be cheaply produced and, critically, because standard immunoassay drug screens cannot reliably distinguish it from fentanyl. In that 2015 scheduling action, the DEA cited at least 39 acetylfentanyl-related fatalities across six states in 2013 and 2014. Its danger lies largely in that detection gap: a person can die from acetylfentanyl while a toxicology screen shows no opioids present.
Fluorofentanyl (para-fluorofentanyl)
Fluorinated fentanyl analogs have become a recurring adulterant in the illicit fentanyl supply in recent years. Para-fluorofentanyl is roughly similar to, or somewhat less potent than, fentanyl itself, but like other analogs it complicates testing: these compounds can be difficult to tell apart from one another and from fentanyl in routine laboratory analysis, creating identification challenges even for well-equipped forensic labs.
The Detection Problem
The most clinically and forensically significant aspect of fentanyl analogs is their systematic evasion of detection. Standard immunoassay drug screens, the tests used in hospital emergency departments, clinical settings, and urine drug testing, are calibrated to detect specific compounds. A pilot study evaluating 30 fentanyl analogs against 19 commercial immunoassay kits found that while immunoassays detected their intended analog and closely related compounds, structurally diverse analogs were poorly detected. Carfentanil in particular was only detected by kits specifically designed for it, meaning a carfentanil overdose would be invisible on a standard fentanyl screen.
This has real consequences. Overdose deaths involving fentanyl analogs are routinely undercounted because many forensic and clinical laboratories do not have the specialized equipment required to identify them, typically liquid chromatography-tandem mass spectrometry (LC-MS/MS, a gold-standard lab method). An investigation may show all the clinical signs of an opioid overdose death but return a toxicology screen negative for opioids, because the specific analog present was not in the test panel.
Why Fentanyl Analogs Evade Detection
Fentanyl analogs are engineered to be difficult to detect by test strips, standard toxicology, and law enforcement. Here’s how each layer of detection works and where it fails.
The Scheduling Race
The legislative and regulatory response to fentanyl analogs has struggled to keep pace with the chemistry. Prior to 2018, the DEA had to individually schedule each new analog. That process could take months, during which the substance was legally uncontrolled. In the 22-month period between May 2016 and February 2018, the DEA individually scheduled 16 distinct newly created fentanyl analogs, with new ones frequently appearing within weeks of a scheduling announcement. In February 2018, the DEA issued an emergency class-wide scheduling order placing all non-scheduled fentanyl-related substances into Schedule I simultaneously. As the DEA’s announcement of class-wide scheduling stated, this action was intended to allow federal agents and prosecutors to take swift action against any fentanyl-related substance regardless of whether it had been individually identified and scheduled. That order was temporary, and after being extended several times it was made permanent by the HALT Fentanyl Act, signed into law in July 2025.
Getting Help When You Don’t Know What You Took
One of the most disorienting aspects of fentanyl analog exposure is that a person may genuinely not know what they used. The drug was sold as something else, the test strip came back negative, and the experience did not match what was expected. That uncertainty is not a reason to delay getting help. It is a reason to be as honest as possible with a treatment provider about what was used, where it came from, and what the experience felt like.
Treatment for opioid use disorder involving fentanyl analogs follows the same clinical pathway as fentanyl treatment. Buprenorphine and methadone address the opioid dependence regardless of which specific compound is involved, though the presence of potent analogs like carfentanil may require adjustments to how treatment is initiated. This is one of several reasons medical supervision matters more with fentanyl-era opioid use than it ever has.
If you or someone you care about is using street fentanyl or any drug that may contain it, the supply is more unpredictable than it has ever been. Effective treatment exists. Getting into it is the most important step a person can take toward a life where that daily uncertainty is no longer part of the picture.